论文部分内容阅读
目的探索表皮生长因子受体(EGFR)低表达、环氧合酶-2(COX-2)高表达和微血管密度(MVD)高表达的分期为T1N0M0的非小细胞肺癌(NSCLC)是否需要接受术后辅助化疗。方法通过非随机对照临床研究的方法,收集早期NSCLC(分期为T1N0M0),并经过免疫组化证实为EGFR低表达、COX-2高表达和MVD高表达的患者为试验组,接受顺铂(DDP)联合诺维本(NVB)化疗;对照组为既往分期相同且免疫组化状态相同的早期NSCLC患者,术后没有接受任何抗肿瘤治疗。结果试验组10例,对照组13例。试验组的中位无病生存期为40个月,而对照组为25个月,但差异无显著性(P=0.079)。结论高危的早期NSCLC(分期为T1N0M0)患者接受化疗后有望取得更好的生存获益,有必要开展大规模的随机对照研究去证实。
Objective To investigate whether low expression of epidermal growth factor receptor (EGFR), high expression of cyclooxygenase-2 (COX-2) and high expression of microvessel density (MVD) in T1N0M0 non-small cell lung cancer After adjuvant chemotherapy. Methods Non-randomized controlled clinical study was performed to collect early stage NSCLC (stage T1N0M0) and confirmed by immunohistochemistry as EGFR low expression, COX-2 overexpression and MVD overexpression in the experimental group receiving cisplatin (DDP ) Combined with nocitrate (NVB) chemotherapy. The control group was an early stage NSCLC with the same stage and the same immunohistochemical status and did not receive any anti-tumor therapy after the operation. Results The experimental group of 10 cases, control group of 13 cases. The median disease-free survival in the experimental group was 40 months compared with 25 months in the control group, but the difference was not significant (P = 0.079). Conclusions High-risk patients with early-stage NSCLC (stage T1N0M0) are expected to achieve better survival benefit after receiving chemotherapy. It is necessary to conduct large-scale randomized controlled studies to confirm.